Events
Satsuma Pharmaceuticals, Inc. announced that John Kollins, Satsuma President and Chief Executive Officer, will present a corporate update at the Evercore ISI HealthCONx Investor Conference, taking place December 3-5, 2019 in Boston.
G1 Therapeutics, Inc., a clinical-stage oncology company, announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference.
Landos Biopharma announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will present at the following conference in New York.
iTeos Therapeutics SA announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the upcoming Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 10:50 a.m.
INmune Bio’s CEO, Dr. R.J. Tesi, will moderate a panel of experts from neuroscience research, clinical trials, and Alzheimer’s drug development.
Tonix Pharmaceuticals Holding Corp. announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting investor meetings at Benchmark’s 8th Annual Discovery 1x1 Conference being held December 4, 2019, at the New York Athletic Club in New York City.
Teewinot Life Sciences Corporation announced Michael Luther Ph.D., Chief Executive Officer, will participate on the Future of Cannabinoid Biosynthesis Panel at the 31st Annual Piper Jaffray Healthcare Conference in New York being held from December 3rd – 5th, 2019 at the Lotte New York Palace.
Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
Myovant Sciences announced that Lynn Seely, M.D., Myovant’s President and CEO, will present at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 10:35 a.m. Eastern Time in Boston, MA.
Kiadis Pharma N.V., a clinical stage biopharmaceutical company, announces that Kiadis will participate in the 2019 Piper Jaffray 31st Annual Healthcare Conference.
PDS Biotechnology Corporation announced that Lauren V. Wood, M.D., Chief Medical Officer of PDS Biotechnology, has been selected to deliver an oral presentation on the Company’s novel T-cell activating immunotherapy platform, Versamune®, at the World Vaccine & Immunotherapy Congress West Coast 2019, taking place on December 2-5, 2019 in San Francisco, CA.
PRESS RELEASES